Navigation Links
Watson Launches Generic PROMETRIUM(R)
Date:3/2/2012

PARSIPPANY, N.J., March 2, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that Watson has launched an authorized generic version of PROMETRIUM® (progesterone, USP) Capsules 100mg and 200mg, as part of an agreement with Abbott Laboratories. Watson began shipping the product today. PROMETRIUM® Capsules are indicated for use in the prevention of endometrial hyperplasia in non hysterectomized postmenopausal women who are receiving conjugated estrogen tablets. They are also indicated for use in secondary amenorrhea.

Under the terms of the supply agreement, Abbott manufactures and supplies Watson with all dosage strengths of the authorized generic product. Watson markets and distributes the product in the United States and the parties will share profits based on sales of the product. Other terms of the agreement have not been disclosed.

For the most recent twelve months ending January 31, 2012, PROMETRIUM® had sales of approximately $198 million, according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets. 

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business.  These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

PROMETRIUM® is a registered trademark of Abbott Laboratories.(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO )CONTACTS:  Investors: 

Patty Eisenhaur  

(862) 261-8141 

  

Media: 

Charlie Mayr 

(862) 261-8030 

 


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson to Present at the Barclays Capital 2012 Global Healthcare Conference
2. Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%
3. Watson to Present at the 2012 RBC Capital Markets Healthcare Conference
4. Watson to Present at the Citi 2012 Global Healthcare Conference
5. Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;
6. Watson Provides Update on Generic Lidoderm® Application
7. Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
8. Watson Confirms Court Stays Preliminary Injunction
9. Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
10. Watson Acquires Ascent Pharmahealth for AU$375 Million
11. Watson to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/11/2017)... 11, 2017  Thornhill Research Inc. ( ... an $8,049,024 USD five-year, firm-fixed-priced, indefinite-quantity/indefinite-delivery contract by ... Commercial Corporation (CCC) ( Ottawa, Ontario, Canada ... administer general anesthesia to patients requiring emergency medical ... US Marine Corps have been a longtime partner ...
(Date:5/10/2017)... 10, 2017 Global Health Intelligence (GHI), ... America , published its 2017 ranking of the ... on extensive data analysis from GHI,s hospitals database for ... for the region. The GHI database covers 86% of the ... than 130 data points for each institution in key areas ...
(Date:5/10/2017)... May 10, 2017 Radiology has become the ... costs have also spiraled to the number one ranking ... radiology than ever before as the most complete and ... patient with lower back pain an MRI may confirm ... for pain, resulting in entirely different treatment protocols.  In ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Boar’s Head Brand®, one of the ... Day entertaining that are sure to satisfy your guests’ flavor cravings, while adding ... cheeses featured in these refreshingly balanced recipes are packed with flavor, creating the ...
(Date:5/26/2017)... ... May 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... is focusing on the Peace Agreements being discussed by President Donald Trump and the ... race to try to speed up peace talks in the continuous battle between Israel ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: ... the creation of published author Laura Weigel Douglas, an avid reader who lives in ... house that sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... “Cactus Jack: ... had on so many others. “Cactus Jack: Against All Odds” is the creation ... Walter D. Hubbard is married to Jack Carlisle’s third child Jane. Walter. ...
(Date:5/24/2017)... ... 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified in ... known for his distinguished expertise and experience in the diagnosis and treatment of vascular ... treating renovascular disease and aortic aneurysm . He is known for his minimally ...
Breaking Medicine News(10 mins):